Ann Lab Med.  2023 Nov;43(6):531-538. 10.3343/alm.2023.43.6.531.

Clot Waveform Analysis for Hemostatic Abnormalities

• Wada H
• Shiraki K
• Matsumoto T
• Shimpo H

• KMID: 2552022
• DOI: http://doi.org/10.3343/alm.2023.43.6.531

Abstract

Clot waveform analysis (CWA) observes changes in transparency in a plasma sample based on clotting tests such as activated partial thromboplastin time (APTT), prothrombin time (PT), and thrombin time (TT). Evidence indicates that not only an abnormal waveform but also peak times and heights in derivative curves of CWA are useful for the evaluation of hemostatic abnormalities. Modified CWA, including the PT with APTT reagent, dilute PT (small amount of tissue factor [TF]-induced clotting factor IX [FIX] activation; sTF/FIXa), and dilute TT, has been proposed to evaluate physiological or pathological hemostasis. We review routine and modified CWA and their clinical applications. In CWA-sTF/FIXa, elevated peak heights indicate hypercoagulability in patients with cancer or thrombosis, whereas prolonged peak times indicate hypocoagulability in several conditions, including clotting factor deficiency and thrombocytopenia. CWA-dilute TT reflects the thrombin burst, whereas clot-fibrinolysis waveform analysis reflects both hemostasis and fibrinolysis. The relevance and usefulness of CWA-APTT and modified CWA should be further investigated in various diseases.

Keyword

Clot waveform analysis; Fibrinolysis; Hemostasis; Hemostatics; Indicators and reagents; Prothrombin time; Thrombin; Thrombocytopenia; Thrombophilia; Thrombosis

Figure

• 

  Fig. 1 Normal CWA-APTT with a FFC, 1st DC, and 2nd DC and three mechanisms of hemostasis. The horizontal double-headed arrow indicates peak width (period of thrombin burst). Abbreviations: FFC, fibrin formation curve; 1st DC, first derivative curve; 2nd DC, second derivative curve; TF, tissue factor; PLs, phospholipids; FXI, clotting factor XI; FXIa, activated FXI.

• 

  Fig. 2 Abnormal waveform in CWA-APTT. The fibrin formation curve is indicated in blue, the 1st DC in red, and the 2nd DC in green. The 1st and 2nd DCs show a bpw. Abbreviations: CWA, clot waveform analysis; APTT, activated partial thromboplastin time; bpw, biphasic waveform; DC, derivative curve.

• 

  Fig. 3 Abnormal APTT and peak height in CWA-APTT. The solid line represents a patient sample, and the dotted line represents a sample from a healthy volunteer. A decreased peak height indicates a major bleeding risk, whereas an increased peak height indicates hypercoagulability. Abbreviations: APTT, activated partial thromboplastin time; CWA, clot waveform analysis.

• 

  Fig. 4 CWA-sTF/FIXa of a patient with a neoplasm and acute cerebral infarction (A) and a patient with thrombocytopenia due to aplastic anemia (B). The fibrin formation curve is indicated in dark blue, the 1st DC (velocity) in pink, and the 2nd DC (acceleration) in light blue. The solid line represents a patient sample, and the dotted line represents a sample from a healthy volunteer. The peak heights of the three curves were significantly higher for patient (A) than for the healthy volunteer and significantly lower for patient (B) than for the healthy volunteer. Abbreviations: CWA, clot waveform analysis; DC, derivative curve; sTF/FIXa, small amount of tissue factor-induced clotting factor IX activation.

• 

  Fig. 5 CWA-TT using PPP (A and C) or PRP (B and D) from a healthy volunteer (A and B) and a patient with cancer (C and D). The fibrin formation curve is indicated in dark blue, the 1st DC (velocity) in pink, and the 2nd DC (acceleration) in light blue. The second peak of the 1st DC is significantly higher for PRP than for PPP and for the patient with cancer than for the healthy volunteer. Abbreviations: CWA, clot waveform analysis; DC, derivative curve; TT, thrombin time; PPP, platelet-poor plasma; PRP, platelet-rich plasma.

• 

  Fig. 6 Standard curves for the FVIII assay by CWA-TT and CWA-APTT in the presence or absence of Emi. The standard curve for CWA-TT is similar between Emi (+) and Emi (–), whereas that for CWA-APTT differs between Emi (+) and Emi (–). Abbreviations: FFC, fibrin formation curve; PH, peak height; CWA, clot waveform analysis; TT, thrombin time; DC, derivative curve; PT, peak time; APTT, activated partial thromboplastin time; Emi, emicizumab.

Reference

1. Wada H, Matsumoto T, Ohishi K, Shiraki K, Shimaoka M. 2020; Update on the clot waveform analysis. Clin Appl Thromb Hemost. 26:1076029620912027. DOI: 10.1177/1076029620912027. PMID: 32862666. PMCID: PMC7466886.

2. Sevenet PO, Depasse F. 2017; Clot waveform analysis: where do we stand in 2017? Int J Lab Hematol. 39:561–8. DOI: 10.1111/ijlh.12724. PMID: 28876509.

3. Nogami K. Clot waveform analysis for monitoring hemostasis. Semin Thromb Hemost. 2022; doi: 10.1055/s-0042-1756706 (Online ahead of print). DOI: 10.1055/s-0042-1756706.

4. Arai S, Kamijo T, Hayashi F, Shinohara S, Arai N, Sugano M, et al. 2021; Screening method for congenital dysfibrinogenemia using clot waveform analysis with the Clauss method. Int J Lab Hematol. 43:281–9. DOI: 10.1111/ijlh.13358. PMID: 33030793.

5. Wada H, Ichikawa Y, Ezaki M, Matsumoto T, Yamashita Y, Shiraki K, et al. 2021; The reevaluation of thrombin time using a clot waveform analysis. J Clin Med. 10:4840. DOI: 10.3390/jcm10214840. PMID: 34768360. PMCID: PMC8585015.

6. Wu Y, Lu Y, Zhang J. 2023; Thrombin generation assay: the present and the future. Blood Coagul Fibrinolysis. 34:1–7. DOI: 10.1097/MBC.0000000000001170. PMID: 36598375.

7. Thakkar M, Rose A, Bednarz B. 2022; Thromboelastography in microsurgical reconstruction: a systematic review. JPRAS Open. 32:24–33. DOI: 10.1016/j.jpra.2021.12.005. PMID: 35242985. PMCID: PMC8857410.

8. Shima M. 2004; Understanding the hemostatic effects of recombinant factor VIIa by clot wave form analysis. Semin Hematol. 41(Suppl 1):125–31. DOI: 10.1053/j.seminhematol.2003.11.021. PMID: 14872433.

9. Matsumoto T, Nogami K, Shima M. 2017; A combined approach using global coagulation assays quickly differentiates coagulation disorders with prolonged aPTT and low levels of FVIII activity. Int J Hematol. 105:174–83. DOI: 10.1007/s12185-016-2108-x. PMID: 27730530.

10. Toh CH, Giles AR. 2002; Waveform analysis of clotting test optical profiles in the diagnosis and management of disseminated intravascular coagulation (DIC). Clin Lab Haematol. 24:321–7. DOI: 10.1046/j.1365-2257.2002.00457.x. PMID: 12452811.

11. Tokutake T, Baba H, Shimada Y, Takeda W, Sato K, Hiroshima Y, et al. 2016; Exogenous magnesium chloride reduces the activated partial thromboplastin times of lupus anticoagulant-positive patients. PLOS ONE. 11:e0157835. DOI: 10.1371/journal.pone.0157835. PMID: 27355205. PMCID: PMC4927146.

12. Matsumoto T, Wada H, Nishioka Y, Nishio M, Abe Y, Nishioka J, et al. 2006; Frequency of abnormal biphasic aPTT clot waveforms in patients with underlying disorders associated with disseminated intravascular coagulation. Clin Appl Thromb Hemost. 12:185–92. DOI: 10.1177/107602960601200206. PMID: 16708120.

13. Toh CH, Samis J, Downey C, Walker J, Becker L, Brufatto N, et al. 2002; Biphasic transmittance waveform in the APTT coagulation assay is due to the formation of a Ca(++)-dependent complex of C-reactive protein with very-low-density lipoprotein and is a novel marker of impending disseminated intravascular coagulation. Blood. 100:2522–9. DOI: 10.1182/blood.V100.7.2522. PMID: 12239165.

14. Shima M, Matsumoto T, Fukuda K, Kubota Y, Tanaka I, Nishiya K, et al. 2002; The utility of activated partial thromboplastin time (aPTT) clot waveform analysis in the investigation of hemophilia A patients with very low levels of factor VIII activity (FVIII:C). Thromb Haemost. 87:436–41. DOI: 10.1055/s-0037-1613023. PMID: 11916076.

15. Maeda K, Wada H, Shinkai T, Tanemura A, Matsumoto T, Mizuno S. 2021; Evaluation of hemostatic abnormalities in patients who underwent major hepatobiliary pancreatic surgery using activated partial thromboplastin time-clot waveform analysis. Thromb Res. 201:154–60. DOI: 10.1016/j.thromres.2021.03.030. PMID: 33862519.

16. Winter WE, Greene DN, Beal SG, Isom JA, Manning H, Wilkerson G, et al. 2020; Clotting factors: clinical biochemistry and their roles as plasma enzymes. Adv Clin Chem. 94:31–84. DOI: 10.1016/bs.acc.2019.07.008. PMID: 31952574.

17. Al-Amer OM. 2022; The role of thrombin in haemostasis. Blood Coagul Fibrinolysis. 33:145–8. DOI: 10.1097/MBC.0000000000001130. PMID: 35239615.

18. Monroe DM, Hoffman M, Roberts HR. 2002; Platelets and thrombin generation. Arterioscler Thromb Vasc Biol. 22:1381–9. DOI: 10.1161/01.ATV.0000031340.68494.34. PMID: 12231555.

19. Konstantinidi A, Sokou R, Parastatidou S, Lampropoulou K, Katsaras G, Boutsikou T, et al. 2019; Clinical application of thromboelastography/thromboelastometry (TEG/TEM) in the neonatal population: a narrative review. Semin Thromb Hemost. 45:449–57. DOI: 10.1055/s-0039-1692210. PMID: 31195422.

20. Matsumoto T, Wada H, Fujimoto N, Toyoda J, Abe Y MR, Ohishi K, et al. 2018; An evaluation of the activated partial thromboplastin time waveform. Clin Appl Thromb Hemost. 24:764–70. DOI: 10.1177/1076029617724230. PMID: 28884611. PMCID: PMC6714873.

21. Katayama H, Matsumoto T, Wada H, Fujimoto N, Toyoda J, Abe Y, et al. 2018; An evaluation of hemostatic abnormalities in patients with hemophilia according to the activated partial thromboplastin time waveform. Clin Appl Thromb Hemost. 24:1170–6. DOI: 10.1177/1076029618757344. PMID: 29439640. PMCID: PMC6714760.

22. Wada H, Shiraki K, Matsumoto T, Ohishi K, Shimpo H, Shimaoka M. 2020; Effects of platelet and phospholipids on clot formation activated by a small amount of tissue factor. Thromb Res. 193:146–53. DOI: 10.1016/j.thromres.2020.06.018. PMID: 32559572.

23. Hasegawa M, Tone S, Wada H, Naito Y, Matsumoto T, Yamashita Y, et al. 2021; The evaluation of hemostatic abnormalities using a CWA-small amount tissue factor induced FIX activation assay in major orthopedic surgery patients. Clin Appl Thromb Hemost. 27:10760296211012094. DOI: 10.1177/10760296211012094. PMID: 34027710. PMCID: PMC8150457.

24. Fan BE, Ng J, Chan SSW, Christopher D, Tso ACY, Ling LM, et al. 2021; COVID-19 associated coagulopathy in critically ill patients: a hypercoagulable state demonstrated by parameters of haemostasis and clot waveform analysis. J Thromb Thrombolysis. 51:663–74. DOI: 10.1007/s11239-020-02318-x. PMID: 33098540. PMCID: PMC7584863.

25. Tripodi A. 2016; Thrombin generation assay and its application in the clinical laboratory. Clin Chem. 62:699–707. DOI: 10.1373/clinchem.2015.248625. PMID: 26955824.

26. Bendetowicz AV, Kai H, Knebel R, Caplain H, Hemker HC, Lindhout T, et al. 1994; The effect of subcutaneous injection of unfractionated and low molecular weight heparin on thrombin generation in platelet rich plasma-a study in human volunteers. Thromb Haemost. 72:705–12. DOI: 10.1055/s-0038-1648946. PMID: 7900078.

27. Wakui M, Fujimori Y, Nakamura S, Kondo Y, Kuroda Y, Oka S, et al. 2019; Distinct features of bivalent direct thrombin inhibitors, hirudin and bivalirudin, revealed by clot waveform analysis and enzyme kinetics in coagulation assays. J Clin Pathol. 72:817–24. DOI: 10.1136/jclinpath-2019-205922. PMID: 31366633.

28. Wakui M, Fujimori Y, Katagiri H, Nakamura S, Kondo Y, Kuroda Y, et al. 2019; Assessment of in vitro effects of direct thrombin inhibitors and activated factor X inhibitors through clot waveform analysis. J Clin Pathol. 72:244–50. DOI: 10.1136/jclinpath-2018-205517. PMID: 30518630.

29. Wada H, Shiraki K, Matsumoto T, Ohishi K, Shimpo H, Sakano Y, et al. 2021; The evaluation of APTT reagents in reference plasma, recombinant FVIII products; Kovaltry^® and Jivi^® using CWA, including sTF/7FIX assay. Clin Appl Thromb Hemost. 27:1076029620976913. DOI: 10.1177/1076029620976913. PMID: 33606948. PMCID: PMC7900842.

30. Bourguignon A, Tasneem S, Hayward CPM. 2022; Update on platelet procoagulant mechanisms in health and in bleeding disorders. Int J Lab Hematol. 44(Suppl 1):89–100. DOI: 10.1111/ijlh.13866. PMID: 36074709.

31. Wada H, Ichikawa Y, Ezaki M, Shiraki K, Moritani I, Yamashita Y, et al. 2021; Clot waveform analysis demonstrates low blood coagulation ability in patients with idiopathic thrombocytopenic purpura. J Clin Med. 10:5987. DOI: 10.3390/jcm10245987. PMID: 34945283. PMCID: PMC8705019.

32. Nogami K, Matsumoto T, Tabuchi Y, Soeda T, Arai N, Kitazawa T, et al. 2018; Modified clot waveform analysis to measure plasma coagulation potential in the presence of the anti-factor IXa/factor X bispecific antibody emicizumab. J Thromb Haemost. 16:1078–88. DOI: 10.1111/jth.14022. PMID: 29645406.

33. Ogiwara K, Furukawa S, Shinohara S, Tabuchi Y, Arai N, Noguchi-Sasaki M, et al. 2023; Anti-idiotype monoclonal antibodies against emicizumab enable accurate procoagulant and anticoagulant assays, irrespective of the test base, in the presence of emicizumab. Haemophilia. 29:329–35. DOI: 10.1111/hae.14662. PMID: 36137299.

34. Kumano O, Suzuki S, Yamazaki M, An Y, Yasaka M, Ieko M, et al. 2023; Evaluation of newly-developed modified diluted prothrombin time reagent in non-valvular atrial fibrillation patients with direct oral anticoagulants: a comparative study with conventional reagents. Int J Lab Hematol. 45:119–25. DOI: 10.1111/ijlh.13971. PMID: 36114152.

35. Wada H, Matsumoto T, Yamashita Y, Ohishi K, Ikejiri M, Katayama N. 2019; Routine measurements of factor VIII activity and inhibitor titer in the presence of emicizumab utilizing anti-idiotype monoclonal antibodies: comment. J Thromb Haemost. 17:555–6. DOI: 10.1111/jth.14395. PMID: 30672649.

36. Onishi T, Shimonishi N, Takeyama M, Furukawa S, Ogiwara K, Nakajima Y, et al. 2022; The balance of comprehensive coagulation and fibrinolytic potential is disrupted in patients with moderate to severe COVID-19. Int J Hematol. 115:826–37. DOI: 10.1007/s12185-022-03308-w. PMID: 35171446. PMCID: PMC8852977.

37. Nogami K, Matsumoto T, Sasai K, Ogiwara K, Arai N, Shima M. 2019; A novel simultaneous clot-fibrinolysis waveform analysis for assessing fibrin formation and clot lysis in haemorrhagic disorders. Br J Haematol. 187:518–29. DOI: 10.1111/bjh.16111. PMID: 31335970.

38. Kobayashi M, Wada H, Fukui S, Mizutani H, Ichikawa Y, Shiraki K, et al. 2021; A clot waveform analysis showing a hypercoagulable state in patients with malignant neoplasms. J Clin Med. 10:5352. DOI: 10.3390/jcm10225352. PMID: 34830633. PMCID: PMC8618625.

39. Menegatti M, Palla R. 2020; Clinical and laboratory diagnosis of rare coagulation disorders (RCDs). Thromb Res. 196:603–8. DOI: 10.1016/j.thromres.2019.09.006. PMID: 31515069.

40. Lowe A, Kitchen S, Jennings I, Kitchen DP, Woods TAL, Walker ID. 2020; Effects of emicizumab on APTT, FVIII assays and FVIII inhibitor assays using different reagents: results of a UK NEQAS proficiency testing exercise. Haemophilia. 26:1087–91. DOI: 10.1111/hae.14177. PMID: 33094895.

41. Wada H, Shiraki K, Matsumoto T, Suzuki K, Yamashita Y, Tawara I, et al. 2022; A clot waveform analysis of thrombin time using a small amount of thrombin is useful for evaluating the clotting activity of plasma independent of the presence of emicizumab. J Clin Med. 11:6142. DOI: 10.3390/jcm11206142. PMID: 36294464. PMCID: PMC9605059.

42. Onishi T, Ishihara T, Nogami K. 2021; Coagulation and fibrinolysis balance in disseminated intravascular coagulation. Pediatr Int. 63:1311–8. DOI: 10.1111/ped.14684. PMID: 33660897.

43. Kamon T, Horie S, Inaba T, Ito N, Shiraki K, Ichikawa Y, et al. 2023; The detection of hypercoagulability in patients with acute cerebral infarction using a clot waveform analysis. Clin Appl Thromb Hemost. 29:10760296231161591. DOI: 10.1177/10760296231161591. PMID: 36872898. PMCID: PMC9989368.